Eurotunnel said it was “astonished” at the decision by the Competition and Markets Authority that officials prohibits the ferry service from operating on certain routes.
The CMA maintained its stance on the Eurotunnel routes between Dover and Calais even after the Competition Appeal Tribunal ordered regulators to take another look at the decision. The former Competition Commission ruled last year that Eurotunnel must cease operations on the route because it gave Eurotunnel too much market share; according to the CMA, Eurotunnel holds 37 percent of the market for short-strait ferry routes.
The assets were acquired by Eurotunnel from defunct rival SeaFrance.
The Tribunal overturned that ruling last December, ordering authorities to reexamine whether Eurotunnel’s acquisition of SeaFrance assets was considered an acquisition of three ships or an acquisition of a business.
But in a ruling announced Friday, the CMA said that a merger situation applies in this case and has maintained the Commission’s original stance on the matter.
”The decision is a denial of the reality of the situation,” Eurotunnel CEO Jacques Gounon said in a statement following the CMA’s announcement. “It penalizes the consumer and puts 600 people out of work without any real justification.”
Eurotunnel vowed to appeal the decision, which ordered the company to cease the services in question within six months.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas